Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-407 SAD and MAD in Healthy Subjects
NCT07022119Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-407 in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at Day 23. Started Jun 2025; status: completed.
02
Drugs
VX-407
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07022119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022119.